MDDepartment of Hematology, ASST Papa Giovanni XXIII, Bergamo, ItalyBergamo, Lombardia, Italy
OC 26.2 - Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: update of an Italian multicenter study
Sunday, June 23, 202415:00 – 15:15 ICT